SUDA Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, has exercised its option to acquire the global intellectual property relating to anagrelide, an anti-thrombotic agent, that has recently shown promise as a novel anticancer agent.
The option also includes access to a number of potential analogues. Following extensive due diligence over the past six months, SUDA believes that it can formulate an oro-mucosal spray of anagrelide by using the Company’s OroMistÒ technology, which could potentially avoid the side-effects associated with the molecule when administered as an oral capsule.
Under the terms of the agreement with UK-based Aluztra Bio Ltd, Aluztra will assign to SUDA the relevant global patents. Aluztra and its partners will be entitled to a low single-digit percentage royalty on direct net sales or a share of income generated by SUDA from commercialisation of an oro-mucosal spray of anagrelide. No other payments are due.
Anagrelide is currently used as an anti-thrombotic agent to reduce elevated levels of platelets. Scientists have identified that platelets also provide essential growth factors that nourish cancer cells and enable them to take hold and develop into tumours. Hence, those patients with the highest platelet numbers are least likely to survive.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.